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Effect of influenza vaccination on excess deaths occurring during
periods of high circulation of influenza: cohort study in elderly
people
Ben G Armstrong, Punam Mangtani, Astrid Fletcher, Sari Kovats, Anthony McMichael, Sam Pattenden, Paul
Wilkinson
Abstract
Objective To estimate the protection against death provided by
vaccination against influenza.
Design Prospective cohort follow up supplemented by weekly
national counts of influenza confirmed in the community.
Setting Primary care.
Participants 24 535 patients aged over 75 years from 73
general practices in Great Britain.
Main outcome measure Death.
Results In unvaccinated members of the cohort daily all cause
mortality was strongly associated with an index of influenza
circulating in the population (mortality ratio 1.16, 95%
confidence interval 1.04 to 1.29 at 90th centile of circulating
influenza). The association was strongest for respiratory deaths
but was also present for cardiovascular deaths. In contrast, in
vaccinated people mortality from any cause was not associated
with circulating influenza. The difference in patterns between
vaccinated and unvaccinated people could not easily be due to
chance (P = 0.02, all causes).
Conclusions This study, using a novel and robust approach to
control for confounding, provides robust evidence of a
protective effect on mortality of vaccination against influenza.
Introduction
A randomised trial showed the effectiveness of vaccination
against laboratory confirmed clinical influenza to be 58%,
1 but
mortality is too rare an end point for reduction in mortality to be
clearly established. Observational studies, mostly on people aged
65 and over, have estimated effects on mortality but are subject
to confounding.
2–7 Confounding “by indication,” whereby sicker
people may be selected for vaccination, biases estimates of effec-
tiveness downwards.
6–9 However, people vaccinated may be
healthier than those not vaccinated, potentially biasing estimates
upwards.
89Problems also exist in identifying deaths due to influ-
enza. Deaths certified with influenza as underlying cause are
known to be a small fraction of deaths due to influenza,
10 leading
researchers to prefer all deaths during influenza epidemics and
due to respiratory or cardiovascular disease as an outcome
measure. However, these deaths include many not caused by
influenza, and this lack of specificity reduces estimates of the
clinical effectiveness of vaccination, particularly as cold related
deaths and other non-influenzal infections such as respiratory
syncytial virus often occur in temperate climates at the same time
of the year as influenza.
11
We sought to overcome these problems by measuring
vaccine effectiveness as the extent to which increases in mortality
during periods of high circulating influenza are diminished in
vaccinated people, rather than by direct comparison of mortality
in vaccinated and unvaccinated people.
Methods
We included all 24 535 people invited to participate in a
randomised trial of targeted screening versus universal
screening of patients aged over 75 years from 73 general
practices in Great Britain.
12 (We did not use the remaining 33 of
the 106 practices in the trial because data on dates of vaccination
against influenza were unavailable for any of the study period—
January 1996 to August 2000.) As a weekly index of influenza
circulating in the population we used the number of clinical
specimens reported to the UK Public Health Laboratory Service
in which influenza A virus was found, according to date of provi-
sion of sample. These counts are known to underestimate very
substantially the actual numbers of people infected by influenza,
but under-ascertainment was likely to be fairly constant over the
study period. Thus the specimen count series reasonably
accurately reflects the week to week variation in cases of
influenza.
13 During this period influenza A H3N2 was the
predominant virus subtype in circulation. We linked daily
regional meteorological and pollution data to the cohort data to
allow control for their potential confounding effect on mortality
from influenza. Here we report on deaths (ascertained by the
Office for National Statistics) to the end of 2000.
We calculated numbers of deaths and cohort members at risk
for each day of the study (January 1996-August 2000), subdivid-
ing the cohort according to vaccination status. Because we
sought to compare (within the vaccinated and unvaccinated
groups) mortality in periods of high circulating influenza with
that in periods of low circulating influenza, precision of the risk
estimates depended in part on duration of the baseline period of
low circulating influenza.We therefore did not restrict analysis to
the conventional influenza season, but included the period
January-August. We excluded the period September-December,
because nearly all (99%) vaccinations took place in this period.
Dividing this period individually for each participant according
to exact date of vaccination would have been complex and may
Details of statistical methods are on bmj.com
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participants each 1 January, according to whether they had been
vaccinated during the previous four months.
Details of the statistical methods are given on bmj.com and
summarised here. We used Poisson regression to obtain
estimates, separately for vaccinated and unvaccinated people, of
association of mortality with circulating influenza adjusted for
confounding by seasonal factors and weather, broadly following
methods developed for daily time series studies of air pollution
and mortality.
14 We chose this approach to analysis to avoid reli-
ance on an assumption that vaccinated people had similar mor-
tality to unvaccinated people outside of influenza periods. The
approach thus did not require adjustment for factors that might
affect this “baseline” mortality. From this model we estimated the
fraction of mortality attributable to influenza when circulating
influenza was at its 90th centile.
15 We estimated vaccine effective-
ness, the proportion of deaths attributable to influenza that were
apparently prevented by the vaccine, from these fractions.
To avoid loss of information due to an arbitrary “flu period”
dichotomy and to control for confounding, we regressed daily
mortality rates on influenza counts in the previous week, using a
Poisson model with separate regression lines in vaccinated and
unvaccinated participants. We adjusted for dependence of
mortality on year, season (month), and low temperature by
including terms for these effects in the model. We also adjusted
for a slight tendency for mortality in vaccinated people to
converge with that in unvaccinated people over time by
including, for the vaccinated group, an additional linear term in
days from 1 January. Adjustment for conventional confounders
such as age at entry and sex was unnecessary because we drew
information only from comparisons between periods of high
and low circulating influenza, over which these variables do not
change appreciably.
Results
Mortality (second and third columns of table) was lower in vacci-
nated people than in unvaccinated people even outside influenza
periods, suggesting that vaccinated people were healthier than
unvaccinated people.However,the difference was greater during
influenza periods, suggesting an effect of vaccination independ-
ent of the selection of healthier people for vaccination.
The fitted regression lines (fig) confirm the lower mortality in
vaccinated people, even when no influenza was present in the
population. They also show that as population influenza counts
increased, mortality in vaccinated people remained stable,
whereas mortality in unvaccinated people increased. The fourth
column of the table shows the slopes of the graphs in the figure
scaled to represent the mortality at the 90th centile of weekly
population influenza counts relative to that when there was no
circulating influenza. (The choice of the 90th centile is arbitrary
but common practice; it does not affect whether confidence
intervals include the null ratio of one.) The fifth column of the
table shows the ratio of the two scaled slopes, providing a robust
estimate of the modification by vaccination of the association of
mortality with influenza. The low ratio for all cause mortality
(0.89), indicating a protective effect of vaccination, could not eas-
ily be explained by chance (P = 0.02). A similar pattern, but less
precisely estimated, occurred for deaths due to cardiovascular
disease (P = 0.09), with a more pronounced effect for deaths due
to respiratory disease (P = 0.002). We found no association of
deaths from other causes with population rates of influenza in
either vaccinated or unvaccinated people.
The proportion of deaths attributable to influenza during
periods of influenza (final column of table) for all cause mortal-
ity was 13.4% in unvaccinated people (1 −RR
−1 =1−1.16
−1) and
Association of mortality with influenza circulating in population: vaccinated and unvaccinated people
Cause of death
No (rate*) of deaths
Association of mortality (95% CI)
with influenza index†
Modification of “influenza”
effect by vaccination‡
Deaths (%)
attributable to
influenza§ In high influenza period Outside high influenza period
All causes
Unvaccinated 564 (13.9) 2305 (9.4) 1.16 (1.04 to 1.29) 1 13.4
Vaccinated 346 (9.7) 1630 (7.7) 1.02 (0.90 to 1.16) 0.89 (0.80 to 0.98) 2.2
Cardiovascular
Unvaccinated 226 (5.6) 1050 (4.3) 1.19 (1.05 to 1.36) 1 16.3
Vaccinated 145 (4.1) 772 (3.7) 1.03 (0.85 to 1.26) 0.87 (0.73 to 1.02) 3.2
Respiratory
Unvaccinated 156 (3.9) 380 (1.6) 1.31 (0.92 to 1.87) 1 23.9
Vaccinated 97 (2.7) 293 (1.4) 1.05 (0.75 to 1.47) 0.80 (0.69 to 0.93) 5.1
Other
Unvaccinated 182 (4.5) 875 (3.6) 1.00 (0.86 to 1.16) 1 0
Vaccinated 104 (2.9) 565 (2.7) 0.98 (0.80 to 1.21) 0.98 (0.82 to 1.17) 0
*Crude annual mortality (%).
†Exponentiated regression coefficient scaled to represent mortality at 90th centile relative to zero influenza period. Adjusted for month (indicators for 40 strata), temperature (linear term for two
week mean of degrees below 20), and number of days since 31 December separately in vaccinated and unvaccinated people.
‡Ratio (95% confidence interval) of exponentiated coefficients in previous column, estimating impact of vaccination on tendency for mortality to increase during periods of high counts of
circulating influenza.
§Fraction of deaths attributable to influenza at 90th centile of circulating influenza.
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Mortality versus population influenza rate by vaccination status. Fitted regression
lines for daily mortality by number of specimens with influenza A reported in the
United Kingdom during the previous week, using Poisson model controlling for
month, temperature, and number of days since 31 December. Mortality is scaled
to be relative to the total cohort average
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−1). The derived estimate of
vaccine effectiveness against deaths associated with influenza,
given by a comparison of these as described above and in the
detailed methods on bmj.com, was (13.4 −2.2)/13.4 = 83%
(95% confidence interval 9% to 100%). The derived estimate of
vaccine effectiveness against death from cardiovascular disease
was 80%, and that for respiratory deaths was 79%, but these were
very imprecisely estimated, with 95% confidence intervals span-
ning the entire meaningful range (0 to 100%).
Discussion
In the vaccinated cohort compared with the unvaccinated
cohort, the tendency of mortality to rise in periods of high influ-
enza infection rates was clearly reduced. This is not easily expli-
cable by chance or confounding. We have substantially reduced
vulnerability to confounding by avoiding direct comparison of
mortality in vaccinated and unvaccinated groups in favour of
comparing vulnerability within each group to increasing mortal-
ity associated with high circulation of influenza. It is hard to
envisage confounding that would cause spurious patterns of
sharply reduced mortality in vaccinated people specifically dur-
ing the high influenza periods.
This approach also improves specificity of outcome. By esti-
mating deaths attributable to influenza statistically, we avoided a
choice between reliance on information from death certificates
or settling for a non-specific outcome. A somewhat similar idea
has been used in the study of malaria.
16 The robustness and
improved outcome specificity of our indirect approach is at the
cost of low precision.Only for all cause mortality and respiratory
mortality was the protection by vaccination statistically
significant at conventional benchmarks. Estimation of vaccine
effectiveness, still more demanding of information under this
approach, was even less precise. Furthermore, the approach is
not immune to information bias. Errors in the index of circulat-
ing influenza would have reduced associations of circulating
influenza with mortality in both vaccinated and unvaccinated
people.Misclassification of vaccination status would have blurred
differences between the groups.
17
Several recent conventional observational studies have
reported vaccine effectiveness against all cause mortality in the
influenza season. A UK study of people aged 55 and over in
1989-90 reported a vaccine effectiveness of 75% (95%
confidence interval 21% to 92%).
3 Among studies of vaccine
effectiveness against all cause mortality in people aged 65 and
over, vaccine effectiveness was 57% (55% to 60%) in a Swedish
cohort study in 1998-2000,
8 24% (3% to 40%) in 1996-7 in the
Netherlands,
7 and 50% in the United States in 1998-2000.
6 A
meta-analysis of 20 earlier observational studies found mean
vaccine effectiveness for all cause mortality of 68% (56% to
76%).
4
These estimates were all lower than our estimate of 83%.
However, these fractions were of all deaths in the influenza sea-
son, rather than of the excess associated with high influenza
periods measured by the more specific estimate of vaccine effec-
tiveness we used in our study.Furthermore,because no compari-
son was made with a non-influenza season, estimates were more
vulnerable to confounding and may have been overestimated
owing to vaccine recipients being healthier than non-recipients.
Control for confounding is possible in conventional studies, but
only for the limited variables measured. One study noted a 12%
(8% to 16%) protective effect against acute respiratory mortality
averaged over a several influenza seasons (1989-90 to 1998-9).
Mortality outside the influenza season, during which vaccination
had no effect on respiratory mortality, was also investigated. An
apparent protective effect against all cause mortality was seen.
9
The authors concluded that the estimate of vaccine effectiveness
against all cause mortality during influenza seasons was probably
upwardly biased due to the “healthy vaccinee” effect. Our study
also shows the presence of the healthy vaccinee effect (second
column of table), but we controlled for this by comparing effects
of influenza rather than mortality in vaccinated and unvacci-
nated people, as described earlier.
The difference in the point estimates of vaccine effectiveness
between the results in the literature and our estimate could thus
be due to differences in methods as discussed above or to
chance, given our wide confidence intervals. In particular, the
greater specificity of outcome from the examination of mortality
during periods of high influenza activity and adjustment for cold
weather may account for the higher effectiveness seen here. In
conclusion,this research adds to evidence that influenza vaccina-
tion protects against mortality from influenza, although
estimates of vaccine effectiveness are imprecise. The novel
method we adopted offers improved control of confounding at
the cost of some precision and is applicable to most studies of
effects of episodic infections on mortality.
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What is already known on this topic
Randomised trials have shown effectiveness of vaccination
against influenza, but mortality is too rare an end point for
a reduction to be clearly established
Observational studies have estimated effects on mortality
but are subject to confounding and to problems in
identifying deaths due to influenza
What this study adds
Mortality in periods of high circulating influenza was clearly
increased in unvaccinated people but not in vaccinated
people, strongly suggesting a protective effect of vaccination
By avoiding direct comparisons of mortality in vaccinated
and unvaccinated people in favour of comparisons of
responses to circulating influenza, we avoided most
confounding
Primary care
BMJ Online First bmj.com page 3 of 41 Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy
of influenza vaccination in elderly individuals: a randomized double-blind
placebo-controlled trial. JAMA 1994;272:1661-5.
2 Christenson B,Lundbergh P,Hedlund J,Ortqvist A.Effects of a large-scale intervention
with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older:
a prospective study. Lancet 2001;357:1008-11.
3 Fleming DM, Watson JM, Nicholas S, Smith GE, Swan AV. Study of the effectiveness of
influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice
database. Epidemiol Infect 1995;115:581-9.
4 Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of
influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann
Intern Med 1995;123:518-27.
5 Hedlund J,Christenson B,Lundbergh P,Ortqvist A.Effects of a large-scale intervention
with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-
up. Vaccine 2003;21:3906-11.
6 Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination
and reduction in hospitalizations for cardiac disease and stroke among the elderly. N
Engl J Med 2003;348:1322-32.
7 Voordouw BC, van der Linden PD, Simonian S, van der Lei J, Sturkenboom MC,
Stricker BH. Influenza vaccination in community-dwelling elderly: impact on mortality
and influenza-associated morbidity. Arch Intern Med 2003;163:1089-94.
8 Christenson B, Lundbergh P. Comparison between cohorts vaccinated and
unvaccinated against influenza and pneumococcal infection. Epidemiol Infect
2002;129:515-24.
9 Mangtani P, Cumberland P, Hodgson C, Roberts J, Cutts F, Hall AJ. A cohort study of
the effectiveness of influenza vaccine in older people, performed using the United
Kingdom general practice research database. J Infect Dis 2004;190:1-10.
10 Ashley J, Smith T, Dunnell K. Deaths in Great Britain associated with the influenza epi-
demic of 1989/90. Population Trends 1991;65:16-20.
11 Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and res-
piratory syncytial virus to community cases of influenza-like illness: an observational
study. Lancet 2001;358:1410-6.
12 Fletcher AE, Jones DA, Bulpitt CJ, Tulloch AJ. The MRC trial of assessment and man-
agement of older people in the community: objectives, design and interventions
[ISRCTN23494848]. BMC Health Serv Res 2002;2:21.
13 Goddard NL, Kyncl J, Watson JM. Appropriateness of thresholds currently used to
describe influenza activity in England. Commun Dis Public Health 2003;6:238-45.
14 Schwartz J, Spix C, Touloumi G, Bacharova L, Barumamdzadeh T, le Tertre A, et al.
Methodological issues in studies of air pollution and daily counts of deaths or hospital
admissions. J Epidemiol Community Health 1996;50(suppl 1):S3-11.
15 Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attrib-
utable risk for multiple risk factors using case-control data. Am J Epidemiol
1985;122:904-14.
16 Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions
for malaria in endemic areas. Stat Med 1994;13:2345-58.
17 Armstrong BG. Effect of measurement error on epidemiological studies of
environmental and occupational exposures. Occup Environ Med 1998;55:651-6.
18 Pattenden S, Nikiforov B, Armstrong BG. Mortality and temperature in Sofia and Lon-
don. J Epidemiol Community Health 2003;57:628-33.
19 Armstrong BG. Fixed factors that modify the effects of time-varying factors: applying
the case-only approach. Epidemiology 2003;14:467-72.
(Accepted 6 July 2004)
doi 10.1136/bmj.38198.594109.AE
London School of Hygiene and Tropical Medicine, London WC1E 7HT
Ben G Armstrong reader
Punam Mangtani lecturer
Astrid Fletcher professor
Sari Kovats lecturer
Anthony McMichael professor
Sam Pattenden lecturer
Paul Wilkinson senior lecturer
Correspondence to: B G Armstrong ben.armstrong@lshtm.ac.uk
Primary care
p a g e4o f4 BMJ Online First bmj.com